trending Market Intelligence /marketintelligence/en/news-insights/trending/wkp77ajI4Zs0X8OL4Z7ydA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Organovo to suspend lead liver drug candidate, explore strategic alternatives

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Organovo to suspend lead liver drug candidate, explore strategic alternatives

Organovo Holdings Inc. is exploring strategic alternatives and a restructuring program to significantly reduce expenses, following the board of directors' decision to discontinue its lead liver drug candidate.

Organovo's stock plunged about 30.3% to 27 cents as of 1:58 p.m. ET on Aug. 7.

Roth Capital Partners will be the San Diego, Calif.-based biotechnology company's financial adviser in the process, Organovo said in its Aug. 7 press release.

According to Organovo, the lead liver program was suspended due to insufficient data supporting its therapeutic benefit, and the development challenges and timeline would not have returned sufficient value to shareholders.

Potential strategic alternatives could include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction.